Regeneron Pharmaceuticals Inc (REGN) Common Stock USD0.001
Sell:$537.99Buy:$538.12
$10.99
(2.01%)
0.92%- This stock can be held in a
Stocks and Shares ISA$10.99
(2.01%)$10.99
(2.01%)Company Information
About this company
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Key people
Key facts
- EPICREGN
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS75886F1075
- Market cap$59.10bn
- Employees15,106
- Shares in issue135.85m
- ExchangeNASDAQ
- IndexS&P 500, NASDAQ 100 Index, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.